Language

English

Publication Date

2-5-2025

Journal

Clinical Infectious Diseases

DOI

10.1093/cid/ciae465

PMID

39325506

PMCID

PMC11797383

PubMedCentral® Posted Date

9-26-2024

PubMedCentral® Full Text Version

Post-print

Abstract

For COVAIL recipients of a coronavirus disease 2019 (COVID-19) Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) and 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer.

Keywords

Adult, Female, Humans, Male, Middle Aged, Antibodies, Neutralizing, Antibodies, Viral, COVID-19, COVID-19 Vaccines, Immunization, Secondary, SARS-CoV-2, Vaccines, Synthetic, correlate of risk, COVID-19 booster, exposure-proximal titer, Omicron, variant vaccine booster

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.